ProCE Banner Activity

CE / CME

Leveraging Metabolic-Driven Treatment Strategies to Target the Origins of NASH

Multimedia

Experts provide a review of therapeutic interventions for NAFLD/NASH, including key recommendations from the latest clinical care guidelines and the safety and efficacy of emerging agents.

Physician Assistants/Physician Associates: 1.50 AAPA Category 1 CME credits

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Nurses: 1.50 Nursing contact hours, including 1.50 hours of pharmacotherapy credit 

Released: December 07, 2022

Expiration: December 06, 2023

No longer available for credit.

Share

Faculty

Manal F. Abdelmalek

Manal F. Abdelmalek, MD, MPH

Professor of Medicine
Division of Gastroenterology and Hepatology
Duke University
Durham, North Carolina

Rohit Loomba

Rohit Loomba, MD, MHSc

Director, NAFLD Research Center
Professor of Medicine
Director of Hepatology
University of California at San Diego
La Jolla, California

Brent A. Tetri

Brent A. Tetri, MD

Professor of Internal Medicine
Division of Gastroenterology and Hepatology
St. Louis University School of Medicine
St. Louis, Missouri

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by an educational grant from

Novo Nordisk Inc

Target Audience

This activity is intended for gastroenterology healthcare professionals, including physicians, nurse practitioners, nurses, and physician associates/physician assistants, and other healthcare professionals who care for patients with NAFLD/NASH.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Detail the pathophysiology shared by obesity, type 2 diabetes, and dyslipidemia that contributes to the genesis of NAFLD
  • Summarize key recommendations from the latest clinical care guidelines for NASH regarding early therapeutic interventions aimed at improving metabolic processes for patients with NAFLD/NASH
  • Compare the efficacy and safety outcomes for NASH drugs in late-phase investigations and potential implications in NASH management

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director Disclosure

Program Director

Manal F. Abdelmalek, MD, MPH

Professor of Medicine
Division of Gastroenterology and Hepatology
Duke University
Durham, North Carolina

Manal F. Abdelmalek, MD, MPH: consultant: Bristol-Myers Squibb, NGM Biopharmaceuticals, Prometic, TaiwanJ; researcher: Allergan, Bristol-Myers Squibb, Galmed, Genfit, Gilead Sciences, Intercept, Madrigal, NGM Biopharmaceuticals, Novartis, TaiwanJ; fees for non-CME/CE services: Genfit, Intercept.

Faculty Disclosure

Primary Author

Rohit Loomba, MD, MHSc

Director, NAFLD Research Center
Professor of Medicine
Director of Hepatology
University of California at San Diego
La Jolla, California

Rohit Loomba MD, MHSc, has no relevant financial relationships to disclose.

Brent A. Tetri, MD

Professor of Internal Medicine
Division of Gastroenterology and Hepatology
St. Louis University School of Medicine
St. Louis, Missouri

Brent Tetri, MD: consultant/advisor: 89bio, Akero, Alimentiv, Allergan, Allysta, Alnylam, Amgen, Arrowhead, Axcella, Boehringer Ingelheim, Bristol-Myers Squibb, Coherus, Cymabay, Durect, Enanta, Fortress, GlaxoSmithKline, Genfit, Gilead Sciences, Glympse, Hepeon, HighTide, HistoIndex, Innovo, Intercept, Ionis, LG Chem, Lipocine, Madrigal, Medimmune, Merck, Mirum, NGM Biopharmaceuticals, Novo Nordisk, Novus Therapeutics, pH-Pharma, Sagimet, Target RWE, Theratechnologies; stock options: HepGene; researcher (paid to institution): Allergan, Bristol-Myers Squibb, Celgene, Cirius, Enanta, Genfit, Gilead, HighTide, Intercept, Inventiva, Madrigal, NGM Biopharmaceuticals.

Planner/Manager Text

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except for Amy Butts, PA-C, DFAAPA, BC-ADM, CDCES, as noted below:

Amy Butts, PA-C, DFAAPA, BC-ADM, CDCES: consultant: Novo Nordisk, Provention Bio, Xeris.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education
Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Education
Credit Designation

The maximum number of hours awarded for this Continuing Nursing Education activity is 1.5 contact hours.

Physician Assistant/Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.5 AAPA Category 1 CME credits. Approval is valid until December 6, 2023. PAs should only claim commensurate with the extent of their participation.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from December 07, 2022, through December 06, 2023:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.

 

Goal


The goal of this activity is to improve clinical knowledge and competency among hepatologists, gastroenterologists, hepatology/gastroenterology advanced practice providers, and other healthcare professionals interested in advances in treating NASH.